- Home
- LPTX vs RMCO Comparison
LPTX vs RMCO Comparison
Compare LPTX & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- RMCO
- Stock Information
- Founded
- LPTX 2011
- RMCO 2021
- Country
- LPTX United States
- RMCO United States
- Employees
- LPTX N/A
- RMCO N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- RMCO Multi-Sector Companies
- Sector
- LPTX Health Care
- RMCO Miscellaneous
- Exchange
- LPTX Nasdaq
- RMCO Nasdaq
- Market Cap
- LPTX 14.7M
- RMCO 14.9M
- IPO Year
- LPTX N/A
- RMCO N/A
- Fundamental
- Price
- LPTX $0.35
- RMCO $1.31
- Analyst Decision
- LPTX Hold
- RMCO
- Analyst Count
- LPTX 1
- RMCO 0
- Target Price
- LPTX N/A
- RMCO N/A
- AVG Volume (30 Days)
- LPTX 3.3M
- RMCO 127.4K
- Earning Date
- LPTX 08-11-2025
- RMCO 08-14-2025
- Dividend Yield
- LPTX N/A
- RMCO 0.40%
- EPS Growth
- LPTX N/A
- RMCO N/A
- EPS
- LPTX N/A
- RMCO N/A
- Revenue
- LPTX N/A
- RMCO $1,568,212.00
- Revenue This Year
- LPTX N/A
- RMCO N/A
- Revenue Next Year
- LPTX N/A
- RMCO N/A
- P/E Ratio
- LPTX N/A
- RMCO N/A
- Revenue Growth
- LPTX N/A
- RMCO 204.08
- 52 Week Low
- LPTX $0.22
- RMCO $0.76
- 52 Week High
- LPTX $4.79
- RMCO $1.88
- Technical
- Relative Strength Index (RSI)
- LPTX 52.39
- RMCO 50.40
- Support Level
- LPTX $0.32
- RMCO $1.18
- Resistance Level
- LPTX $0.36
- RMCO $1.35
- Average True Range (ATR)
- LPTX 0.03
- RMCO 0.17
- MACD
- LPTX 0.01
- RMCO -0.02
- Stochastic Oscillator
- LPTX 86.94
- RMCO 15.00
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.